Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING
Tech Brief (Sept. 26): Trump Approves TikTok Deal
Yangtze Memory’s Parent Restructures to Pave Way for IPO Amid Sanctions Pressures
Xiaomi Ups the Stakes in Premium Market With iPhone-Style 17 Series
LATEST
GPT Weekly: Nvidia to Invest $100 Billion in OpenAI
Tech Brief (Sept. 26): Trump Approves TikTok Deal
Xiaomi Ups the Stakes in Premium Market With iPhone-Style 17 Series
Yangtze Memory’s Parent Restructures to Pave Way for IPO Amid Sanctions Pressures
Tech Brief (Sept. 25): Alibaba Launches AI Models
Alibaba Bets Big on ‘AI + Cloud’ With New Models, Nvidia Deal
GlobalFoundries Boosts U.S. Investment, Adds China Fabs to Meet Auto Chip Demand
Tech Brief (Sept. 24): Mercedes-Benz, ByteDance Partner on In-Car AI
Tech Brief (Sept. 23): Nvidia Plans $100 Billion Investment in OpenAI for AI Data Centers
Tech Brief (Sept. 22): Trump Says Murdoch Family May Be Involved in TikTok Deal
GPT Weekly: CoreWeave Secures $6.3 Billion Nvidia Order
Huawei Unveils Three-Year AI Chip Roadmap as Nvidia Faces Setbacks in China
Tencent Cloud Shuns Price War in Intensifying AI Race
China’s Regulator Ramps Up Push to Curb Food Delivery Subsidy War
Chinese Robot Startup Unitree Gears Up for Market Debut
China Enforces AI Content Labeling Rules to Curb Misuse
Tech Brief (Sept. 2): China Rolls Out Mandatory AI Labeling
Meituan Enters Open-Source AI Race With LongCat Model
Tech Brief (Aug. 29): SenseTime Reports Strong AI Growth
All Hail the Driverless Taxis as China Eyes a $183 Billion Market
Deadly 'Super Fungus' Fuels China Pharma Stock Surge

By Wang Luyao and Han Wei / Apr 12, 2019 03:40 AM / Finance

Photo: VCG

Photo: VCG

A number of Chinese pharma stocks surged Thursday after reports confirming domestic infections of a deadly fungus that is spreading around the globe, although none of the companies has a proven therapy.

Share prices of antifungal drugmakers listed in Shanghai and Shenzhen have climbed over the past few days. Several stocks rose by their 10% daily limits, including Jiangsu Lianhuan Pharmaceutical Co. and Jiangsu Sihuan Bioengineering Co.

At least 18 people in China are known to have been infected in recent years with Candida auris, although no deaths have been reported, Caixin learned. The fungus, which can cause deadly infections of the bloodstream and wounds in people with weakened immune systems, is often resistant to common antifungal drugs and is described as a “serious global health threat” by the U.S. Centers for Disease Control and Prevention.

Analysts said the pharma stock surges are mainly driven by hot money as none of the companies has been proven to have effective therapy against Candida auris.


Share this article
Open WeChat and scan the QR code